Rosemont Pharmaceuticals
Ed Cahill is currently serving as the Chief Scientific Officer at Rosemont Pharmaceuticals since July 2022. Prior to this, they were the Head of Early MSAT - Global Technical Operations at Amicus Therapeutics from October 2019 to July 2022. Ed also held various roles at Teva Pharmaceuticals from October 2006 to October 2019, including Senior Director of Manufacturing, Science and Technology, Head of New Sterile Technology, and Global Sterile Technology Manager. They previously worked at AstraZeneca as a Product Development Manager from 2000 to 2006 and at Medeva as a Team Leader from 1994 to 2000.
This person is not in the org chart
Rosemont Pharmaceuticals
At Rosemont our mission is to be a rapid developer, reliable manufacturer and global supplier of novel-delivery, patient-focused medicines. Our ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them. We are highly respected in the industry and have been instrumental in establishing best practice for the care of patients with swallowing difficulties. Rosemont advocate the use of liquid medication over manipulating solid dose medications and we have a range of educational materials designed for healthcare professionals which focuses on key patient groups and their medication management challenges. At Rosemont we have a portfolio of over 130 oral liquid medicines across a range of therapeutic areas including 70 licensed products. All of our products, both licensed and ‘specials’ are made to the same exacting standards under GMP. Our UK range also includes 9 products licensed for use with PEG/NG tubes. We are always seeking to expand our range of medicines and covert our ‘specials’ to licensed product wherever possible.